Nikhil C. Munshi, MD

Adjunct Associate Professor, Boston University Chobanian & Avedisian School of Medicine

Biography

Dr. Nikhil Munshi received his medical degree from Maharaja Sayajirao University, followed by an internship and residency in internal medicine at Shri Sayaji General Hospital and Maharaja University in India. He then completed an oncology fellowship at Johns Hopkins Ocology Center, and an hematology/oncology fellowhip at Indiana University Medical Center. Dr. Munshi is currently professor of medicine in the Department of Medicine at Harvard Medical School, as well as an attending physician at VA Boston Healthcare System and Dana-Farber Cancer Institute.

A diplomate of American Board of Internal Medicine, Dr. Munshi is also on the Board of Directors of the International Myeloma Society. He is a member of numerous professional associations including the Indian Medical Association, Physician’s Association of India, Indian Association of Clinical Oncology, American Medical Association, American Society of Clinical Oncology, and the American Society of Hematology, among others. In addition, he is on the editorial board of Clinical Lymphoma and Myeloma and Personalized Medicine in Oncology and is an ad hoc reviewer for numerous professional journals.

Dr. Munshi’s current laboratory research and clinical activities specialize in plasma cell disorders with a focus on understanding oncogenomic changes in myeloma and developing a translational research programs in myeloma. He has also established a Myeloma Initiative at Veterans Administration Hospitals, a comprehensive program bringing together, for the first time, all major VA hospitals across the country to focus on cutting-edge joint clinical studies.

Publications

  • Published 5/28/2026

    Nadeem O, Redd RA, Barth PM, Bayliss TJ, Laubach JP, Bianchi G, Mo CC, Reagan JL, Midha S, Sperling AS, Liu Y, Hartley-Brown MA, Chuma MP, Nicholson T, Benjamin EJ, Distaso A, Regan E, Hof AMV, Dahill AJ, Goldbaum R, Mohammadi K, Lewis A, Poda R, Munshi NC, Anderson KC, Ghobrial IM, Richardson PG. A phase I/II study of twice-weekly ixazomib plus pomalidomide and dexamethasone in relapsed and refractory multiple myeloma. Haematologica. 2026 May 28. PMID: 42206445.

    Read at: PubMed

  • Published 5/14/2026

    Du T, Fang T, Pillai S, Ray A, Wang M, Wan X, Wen K, Liu Y, Xu J, Musa MA, Liu X, Fulciniti M, Munshi NC, Garbicz F, Carrasco RD, Yao Y, Zhang Z, Song Y, Anderson KC. Proteasome subunit PSMD1 is a key therapeutic target in multiple myeloma. Blood. 2026 May 14; 147(20):2344-2357. PMID: 41632828.

    Read at: PubMed

  • Published 5/1/2026

    Moreau P, Kumar S, Raje NS, Mateos MV, Munshi NC, Rajkumar SV, Miguel JFS, Anderson KC. The International Myeloma Society Honors the Life and Legacy of Myeloma Pioneer Brian G. M. Durie, MD, PhD (1942-2025). Clin Lymphoma Myeloma Leuk. 2026 May; 26(5):261-264. PMID: 42103397.

    Read at: PubMed

  • Published 4/23/2026

    Cumerlato M, Maccagno M, Labrador M, Luciano B, Mereu E, Porro M, Bandini C, Furlan M, Maisano D, D'Agostino M, Larocca A, Gay F, Tamburrini A, Anselmi F, Porporato PE, Oliviero S, Bruno B, Morelli E, Munshi N, Piva R. Bedaquiline amplifies proteasome inhibitor efficacy and overcomes resistance in multiple myeloma. Haematologica. 2026 Apr 23. PMID: 42021688.

    Read at: PubMed

  • Published 4/23/2026

    DuMontier C, Cronin AM, Hshieh TT, Sanyal A, Mozessohn L, Abdallah MM, DeAngelo DJ, Munshi NC, Stone RM, Soiffer RJ, Driver JA, Abel GA. Prevalence and impact of frailty assessed using standard geriatrics tools in older adults with blood cancers. Haematologica. 2026 Apr 23. PMID: 42021681.

    Read at: PubMed

View All 651 Publications:   View Full Profile in BUMC

Websites

Education

  • Maharaja Sayajirao University, MBBS
  • Maharaja Sayajirao University, MD

View all profiles